ReviewClinical drug investigation2022

Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17.

Ombretta Viapiana et al.PubMed ↗Publisher ↗

No numbers read from the abstract.